WVE
- Wave Life Sciences Ltd.
()
Overview
Company Summary
Wave Life Sciences Ltd. (WVE) is a biotechnology company that specializes in the discovery, development, and commercialization of nucleic acid-based therapeutics for genetic diseases.
The company focuses on developing novel treatments for genetic disorders that have been challenging to address using traditional small molecule or protein-based approaches. By leveraging its proprietary technology platform, called Stereochemistry and Conformational Effects of Locked Nucleic Acid (LNAplus�), Wave Life Sciences aims to target the underlying cause of genetic diseases at the genetic level.
Wave Life Sciences' approach involves designing and developing chemically modified synthetic oligonucleotides that can modulate the expression of disease-causing genes. These oligonucleotides are specifically designed to interact with the target gene's mRNA (messenger RNA), either towards its degradation or stabilization, with the ultimate goal of either reducing or increasing the production of the target protein.
The company's platform allows for precise and selective targeting of disease-causing genetic mutations and enables the development of therapeutic candidates for conditions such as Huntington�s disease, Duchenne muscular dystrophy, genetic ALS (amyotrophic lateral sclerosis), and various other neurological and genetic conditions.
Wave Life Sciences employs a rigorous and systematic approach to identify and develop potential drug candidates, conducting preclinical studies and utilizing advanced technologies and computational modeling to optimize the therapeutic effect and minimize potential side effects.
Ultimately, the goal of Wave Life Sciences is to provide innovative treatment options for patients with genetic diseases, potentially improving their quality of life and addressing significant unmet medical needs in these clinical areas.